Protirelin

CHEMBL1472 Phase 4 Approuvé Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
362.4 g/mol
LogP
-2.5
Phase
4

Protirelin (thyrotropin-releasing hormone, TRH) is a synthetic tripeptide hypothalamic hormone that stimulates the pituitary release of thyroid-stimulating hormone (TSH) and prolactin by binding to specific G-protein-coupled TRH receptors on thyrotrophs and lactotrophs. It is used diagnostically as a provocative test for evaluating thyroid function and pituitary TSH reserve, and is under investigation as a treatment for thyroid cancer.

Masse moléculaire

362,3800 g/mol

LogP

-2,50

TPSA

150,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Mécanisme d'action

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1

InChI

InChI=1S/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1

Molecular Formula

C16H22N6O4

HBD / HBA

4 / 5

Liaisons Rotatives

6

Atomes Lourds

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Protirelin (thyrotropin-releasing hormone, TRH) is a synthetic tripeptide hypothalamic hormone that stimulates the pituitary release of thyroid-stimulating hormone (TSH) and prolactin by binding to specific G-protein-coupled TRH receptors on thyrotrophs and lactotrophs. It is used diagnostically as a provocative test for evaluating thyroid function and pituitary TSH reserve, and is under investigation as a treatment for thyroid cancer.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Protirelin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1472. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 638678. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.